Progyny reports Q3 adjusted EPS 40c, consensus 13c

Reports Q3 revenue $286.63M, consensus $296.88M. “The utilization rate in the third quarter was consistent with the expectations we outlined in August. However, the members that began their journey utilized their benefits in a manner inconsistent with long-term patterns, taking longer to progress through their treatment and, therefore, consuming fewer treatments overall, resulting in lower-than-expected revenue and profitability this quarter,” said Pete Anevski, Chief Executive Officer of Progyny (PGNY).